India to United States: Anastrozole Export Trade Route

To import Anastrozole formulations into the United States, the following approvals and registrations are mandatory:

• Abbreviated New Drug Application (ANDA): Generic drug manufacturers must submit an ANDA to the FDA, demonstrating that their product is bioequivalent to the reference listed drug. The ANDA should be formatted in the Common Technical Document (CTD) or electronic CTD (eCTD) format. Approval timelines can vary, but the FDA aims to review standard ANDAs within 10 months.

• Drug Establishment Registration: Foreign manufacturers must register their facilities with the FDA and list all drugs intended for commercial distribution in the U.S. This registration must be renewed annually.

• Labeling Compliance: Product labeling must meet FDA requirements, including accurate drug information, usage instructions, and safety warnings.

• Importation Procedures: Each shipment must be declared to the FDA and U.S. Customs and Border Protection (CBP). Importers should provide necessary documentation, such as the Certificate of Analysis (CoA) and shipping records, to facilitate the import process.

• Facility Fees: Under the Generic Drug User Fee Amendments (GDUFA), facilities involved in manufacturing, testing, or packaging generic drugs must pay annual fees. Failure to pay these fees can result in products being deemed misbranded and denied entry into the U.S.

Indian manufacturers exporting Anastrozole formulations to the U.S. must comply with the following Good Manufacturing Practice (GMP) standards:

• FDA GMP Compliance: Facilities must adhere to the FDA's GMP regulations, ensuring consistent product quality and safety.

• FDA Inspections: The FDA conducts periodic inspections of foreign manufacturing facilities to verify compliance with GMP standards.

• Recent Inspections and Actions: The FDA regularly inspects Indian pharmaceutical facilities. For instance, in March 2026, the FDA issued a warning letter to an Indian manufacturer for GMP violations, highlighting the importance of maintaining compliance to avoid regulatory actions.

Several regulatory changes have impacted Indian pharmaceutical exports to the United States in the past 18 months:

• GDUFA III Implementation (October 2024): The third iteration of GDUFA introduced revised fee structures and performance goals, affecting timelines and costs for ANDA approvals.

• Mutual Recognition Agreement (MRA) Expansion (January 2025): The U.S. and India expanded their MRA to include GMP inspections, potentially reducing redundant inspections and facilitating smoother trade.

• Revised Guidance on Data Integrity (June 2025): The FDA issued updated guidance emphasizing the importance of data integrity in manufacturing processes, impacting documentation practices for Indian exporters.

Staying informed about these developments is crucial for Indian manufacturers to ensure compliance and maintain uninterrupted access to the U.S. market.

In 2024, the global aromatase inhibitor drug class market was valued at $4.1 billion, with projections indicating growth to $4.3 billion in 2025 and reaching $6.7 billion by 2033, reflecting a compound annual growth rate (CAGR) of 5.5%. Non-steroidal aromatase inhibitors like Anastrozole dominate this market segment, accounting for approximately 65% of the market share in 2024. This dominance is attributed to their favorable safety profiles and widespread clinical adoption.

The demand for Anastrozole in the United States is primarily driven by the rising incidence of hormone receptor-positive breast cancer, which constitutes a significant portion of breast cancer cases. Additionally, the aging population contributes to increased demand, as the risk of breast cancer escalates with age. While specific data on the proportion of Anastrozole formulations imported versus domestically manufactured in the United States is not readily available, the substantial import figures from India underscore the country's significant role in supplying the U.S. market.

Pharmaceutical products classified under HS code 30049099, which includes finished formulations containing Anastrozole, are subject to specific import regulations in the United States. The Most-Favored-Nation (MFN) import duty rate for this category is 0%, indicating that these products can be imported duty-free. This favorable tariff structure facilitates the importation of pharmaceutical formulations, including those containing Anastrozole, into the U.S. market.

Regarding trade agreements, the United States and India do not have a Free Trade Agreement (FTA) that specifically affects pharmaceutical tariffs. However, the Generalized System of Preferences (GSP) program, which previously provided preferential duty-free entry for certain products from developing countries, including India, expired in December 2020 and has not been renewed as of March 2026. Despite this, the MFN duty-free status for pharmaceutical products under HS code 30049099 remains in effect, ensuring that imports of Anastrozole formulations from India continue to benefit from a 0% import duty rate.

India is a dominant supplier of Anastrozole formulations to the United States, accounting for approximately 90.4% of India's total Anastrozole formulation exports, valued at $100.2 million USD across 219 shipments. The leading Indian exporters include INTAS PHARMACEUTICALS LIMITED ($92.3 million), EUGIA PHARMA SPECIALITIES LIMITED ($3.0 million), and ZYDUS LIFESCIENCES LIMITED ($2.5 million).

While specific data on other major countries supplying Anastrozole to the United States is not provided, India's substantial export figures highlight its significant market share. The competitive pricing of Indian pharmaceutical manufacturers, coupled with their capacity to produce high-quality generic formulations, positions India favorably against competitors from regions such as China and the European Union. This competitive edge is further supported by India's robust pharmaceutical manufacturing infrastructure and compliance with international quality standards, making it a preferred source for Anastrozole formulations in the U.S. market.

India is a leading global supplier of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume. The country's pharmaceutical industry is supported by a vast network of manufacturing facilities, many of which are certified by international regulatory bodies. As of 2024, India has 396 facilities registered with the U.S. Food and Drug Administration (FDA) under the Generic Drug User Fee Amendments (GDUFA) program, indicating compliance with stringent manufacturing standards.

The cost structure of Indian pharmaceutical manufacturing is favorable due to lower labor and operational expenses, enabling competitive pricing for finished dosage forms such as tablets and capsules. This cost efficiency, combined with adherence to international quality standards, positions India as a preferred source for Anastrozole formulations.

When comparing Anastrozole formulations from India, China, and the European Union (EU), several factors come into play:

• Price per Unit: Generic Anastrozole is available at prices as low as USD 0.50 per tablet in regions like India and China, maintaining a significant cost advantage over Western markets.

• Quality Perception: Indian manufacturers have a strong reputation for quality, with numerous facilities holding WHO-GMP and FDA approvals. Chinese manufacturers have faced challenges related to regulatory compliance, with approximately 40% of API manufacturing facilities receiving FDA citations since 2020. EU manufacturers are known for high-quality standards but often at higher price points.

• Regulatory Acceptance in the United States: Indian pharmaceutical companies have a robust presence in the U.S. market, with many facilities approved by the FDA. Chinese manufacturers have faced regulatory challenges, impacting their acceptance. EU manufacturers are generally well-accepted but may not offer the same cost advantages.

• Supply Reliability Track Record: Indian manufacturers have demonstrated a reliable supply chain with consistent delivery to the U.S. market. Chinese manufacturers have faced supply chain disruptions due to regulatory and quality issues. EU manufacturers maintain reliable supply chains but at higher costs.

The India-United States supply chain for Anastrozole formulations is robust, supported by significant manufacturing capacity and compliance with international regulatory standards. Indian facilities are equipped with advanced packaging and cold chain capabilities to ensure product integrity during transit.

Recent data indicates that Indian manufacturers have maintained a consistent supply of Anastrozole formulations to the U.S. market without significant disruptions. Regulatory compliance is strong, with numerous facilities holding FDA and WHO-GMP certifications. Manufacturers are continually expanding capacity to meet growing demand, ensuring a stable supply chain.

For U.S. buyers sourcing Anastrozole formulations from India, the following strategies are recommended:

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions.

• Understand Minimum Order Quantities (MOQs): MOQs can vary; it's essential to negotiate terms that align with your demand forecasts.

• Negotiate Favorable Payment Terms: Common terms include letters of credit or advance payments; establish terms that balance risk and cash flow.

• Conduct Thorough Supplier Qualification: Evaluate potential suppliers based on regulatory compliance, manufacturing capacity, and quality assurance practices.

• Monitor Regulatory Compliance: Regularly review suppliers' adherence to FDA and WHO-GMP standards to ensure consistent product quality.

By following these recommendations, U.S. buyers can establish a reliable and cost-effective supply chain for Anastrozole formulations from India.

By meticulously following these guidelines, United States companies can establish reliable partnerships with Indian manufacturers, ensuring the consistent supply of high-quality Anastrozole formulations.